Redhill Biopharma (RDHL) Competitors $2.19 +0.06 (+2.82%) Closing price 07/11/2025 03:59 PM EasternExtended Trading$2.15 -0.04 (-1.78%) As of 07/11/2025 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock RDHL vs. CARM, MRKR, CTXR, RVPH, PMN, GOVX, PRPH, ALLR, HOTH, and LEXXShould you be buying Redhill Biopharma stock or one of its competitors? The main competitors of Redhill Biopharma include Carisma Therapeutics (CARM), Marker Therapeutics (MRKR), Citius Pharmaceuticals (CTXR), Reviva Pharmaceuticals (RVPH), Promis Neurosciences (PMN), GeoVax Labs (GOVX), ProPhase Labs (PRPH), Allarity Therapeutics (ALLR), Hoth Therapeutics (HOTH), and Lexaria Bioscience (LEXX). These companies are all part of the "pharmaceutical products" industry. Redhill Biopharma vs. Its Competitors Carisma Therapeutics Marker Therapeutics Citius Pharmaceuticals Reviva Pharmaceuticals Promis Neurosciences GeoVax Labs ProPhase Labs Allarity Therapeutics Hoth Therapeutics Lexaria Bioscience Carisma Therapeutics (NASDAQ:CARM) and Redhill Biopharma (NASDAQ:RDHL) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, analyst recommendations, dividends, media sentiment, institutional ownership, profitability, valuation and earnings. Do insiders and institutionals hold more shares of CARM or RDHL? 44.3% of Carisma Therapeutics shares are held by institutional investors. Comparatively, 7.2% of Redhill Biopharma shares are held by institutional investors. 12.6% of Carisma Therapeutics shares are held by company insiders. Comparatively, 6.8% of Redhill Biopharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Which has more volatility and risk, CARM or RDHL? Carisma Therapeutics has a beta of 1.92, meaning that its stock price is 92% more volatile than the S&P 500. Comparatively, Redhill Biopharma has a beta of 4.22, meaning that its stock price is 322% more volatile than the S&P 500. Do analysts prefer CARM or RDHL? Carisma Therapeutics currently has a consensus target price of $1.93, suggesting a potential upside of 381.25%. Given Carisma Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Carisma Therapeutics is more favorable than Redhill Biopharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Carisma Therapeutics 0 Sell rating(s) 5 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.43Redhill Biopharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the media prefer CARM or RDHL? In the previous week, Carisma Therapeutics had 1 more articles in the media than Redhill Biopharma. MarketBeat recorded 2 mentions for Carisma Therapeutics and 1 mentions for Redhill Biopharma. Redhill Biopharma's average media sentiment score of 1.87 beat Carisma Therapeutics' score of 0.93 indicating that Redhill Biopharma is being referred to more favorably in the news media. Company Overall Sentiment Carisma Therapeutics Positive Redhill Biopharma Very Positive Which has preferable earnings and valuation, CARM or RDHL? Redhill Biopharma has lower revenue, but higher earnings than Carisma Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCarisma Therapeutics$19.63M0.85-$60.48M-$1.56-0.26Redhill Biopharma$8.04M0.63-$8.27MN/AN/A Is CARM or RDHL more profitable? Redhill Biopharma has a net margin of 0.00% compared to Carisma Therapeutics' net margin of -254.28%. Company Net Margins Return on Equity Return on Assets Carisma Therapeutics-254.28% N/A -137.38% Redhill Biopharma N/A N/A N/A SummaryCarisma Therapeutics beats Redhill Biopharma on 9 of the 14 factors compared between the two stocks. Get Redhill Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for RDHL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding RDHL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RDHL vs. The Competition Export to ExcelMetricRedhill BiopharmaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.89M$2.74B$5.62B$9.10BDividend YieldN/A1.79%5.24%4.00%P/E RatioN/A9.4228.0020.27Price / Sales0.63714.12429.5999.28Price / CashN/A165.3637.4658.16Price / Book-0.604.608.045.49Net Income-$8.27M$31.26M$3.18B$250.45M7 Day Performance8.68%4.80%3.60%4.73%1 Month Performance12.89%5.42%4.00%7.61%1 Year Performance-99.10%-4.36%29.52%16.39% Redhill Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RDHLRedhill BiopharmaN/A$2.19+2.8%N/A-99.1%$4.89M$8.04M0.00210Positive NewsCARMCarisma Therapeutics3.1494 of 5 stars$0.39-2.2%$1.93+391.6%-66.7%$16.74M$19.63M-0.2520MRKRMarker Therapeutics4.6593 of 5 stars$1.53+4.8%$13.17+760.6%-64.8%$16.52M$6.59M-1.1560News CoverageCTXRCitius Pharmaceuticals3.1653 of 5 stars$1.59+3.9%$53.00+3,233.3%-91.9%$16.27MN/A0.0020High Trading VolumeRVPHReviva Pharmaceuticals3.0849 of 5 stars$0.38+12.9%$9.00+2,261.6%-69.2%$16.20MN/A-0.485Gap UpHigh Trading VolumePMNPromis Neurosciences3.361 of 5 stars$0.48+0.7%$4.50+830.1%-81.5%$15.70MN/A-9.685Positive NewsGap UpGOVXGeoVax Labs2.2948 of 5 stars$0.87-9.8%$11.10+1,182.2%-76.7%$15.29M$3.95M-0.2410Analyst RevisionPRPHProPhase Labs0.6765 of 5 stars$0.39+6.6%N/A-87.8%$15.25M$6.77M-0.31130Positive NewsALLRAllarity Therapeutics0.6664 of 5 stars$1.01+1.0%N/A-83.1%$15.08MN/A0.0010Gap DownHOTHHoth Therapeutics2.8568 of 5 stars$1.17+3.5%$4.00+241.9%+58.2%$14.93MN/A-1.034LEXXLexaria Bioscience2.3473 of 5 stars$0.87+2.5%$7.00+704.6%-68.7%$14.91M$460K-1.477 Related Companies and Tools Related Companies Carisma Therapeutics Competitors Marker Therapeutics Competitors Citius Pharmaceuticals Competitors Reviva Pharmaceuticals Competitors Promis Neurosciences Competitors GeoVax Labs Competitors ProPhase Labs Competitors Allarity Therapeutics Competitors Hoth Therapeutics Competitors Lexaria Bioscience Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RDHL) was last updated on 7/12/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | Sponsored"I'm risking my reputation on this"Most people think you need thousands to profit from crypto. But this free book exposes how even small inves...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Redhill Biopharma Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Redhill Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free RDHL Stock Alerts